|Trade names||Banzel, Inovelon|
|Main uses||Lennox–Gastaut syndrome, partial seizures|
|Side effects||Sleepiness, headache, dizziness, vomiting|
|By mouth (tablets)|
|Typical dose||200 to 400 mg (10mg/kg)|
|Bioavailability||85% (under fed conditions); tmax = 4–6 hours|
|Metabolism||Carboxylesterase-mediated hydrolysis (CYP not involved)|
|Elimination half-life||6–10 hours|
|Chemical and physical data|
|Molar mass||238.198 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Common side effects include sleepiness, headache, dizziness, and vomiting. Other symptoms may include drug reaction with eosinophilia and systemic symptoms, suicide, and poor coordination. Safety in pregnancy is unclear. It is a triazole derivative that is believed to work by attaching to sodium channels in the brain.
Rufinamide was approved for medical use in Europe in 2007 and the United States in 2008. It is available as a generic medication. In the United Kingdom a dose of 800 mg per day costs the NHS costs about £100. In the United States this amount costs about 425 USD per month.
Several recent clinical trials suggest that the drug has efficacy for partial seizures 
Mechanism of action
The mechanism of action of rufinamide is not fully understood. There is some evidence that rufinamide can modulate the gating of voltage-gated sodium channels, a common target for antiepileptic drugs. A recent study indicates subtle effects on the voltage-dependence of gating and the time course of inactivation in some sodium channel isoforms that could reduce neuronal excitability. However, this action cannot explain the unique spectrum of activity of rufinamide.
- "Rufinamide Monograph for Professionals". Drugs.com. Retrieved 19 October 2021.
- "Inovelon". Retrieved 19 October 2021.
- "Banzel- rufinamide tablet, film coated Banzel- rufinamide suspension". DailyMed. 15 April 2020. Retrieved 21 October 2020.
- "Rufinamide (Banzel) Use During Pregnancy". Drugs.com. Retrieved 19 October 2021.
- "Rufinamide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 19 October 2021.
- BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 343. ISBN 978-0-85711-369-6.CS1 maint: date format (link)
- Brodie MJ, Rosenfeld WE, Vazquez B, Sachdeo R, Perdomo C, Mann A, Arroyo S (August 2009). "Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial". Epilepsia. 50 (8): 1899–909. doi:10.1111/j.1528-1167.2009.02160.x. PMID 19490053. S2CID 38485532.
- Rogawski, M. A. (2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Research. 69 (3): 273–94. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450.
- Striano, P.; McMurray, R.; Santamarina, E.; Falip, M. (2018). "Rufinamide for the treatment of Lennox-Gastaut syndrome: Evidence from clinical trials and clinical practice". Epileptic Disorders. 20 (1): 13–29. doi:10.1684/epd.2017.0950. PMID 29313492.
- Rogawski, A.; Löscher, W. (Jul 2004). "The neurobiology of antiepileptic drugs". Nature Reviews. Neuroscience. 5 (7): 553–564. doi:10.1038/nrn1430. ISSN 1471-003X. PMID 15208697. S2CID 2201038.
- Gilchrist, J; Dutton, S; Diaz-Bustamante, M; McPherson, A; Olivares, N; Kalia, J; Escayg, A; Bosmans, F (2014). "Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents". ACS Chemical Biology. 9 (5): 1204–12. doi:10.1021/cb500108p. PMC 4027953. PMID 24635129.